Oncimmune (ONC.L)

Executive Summary

Oncimmune is a UK-based diagnostics company leveraging its proprietary ImmunoINSIGHTS platform to discover antibody and autoantibody biomarker signatures. The platform provides deep insights into the B cell repertoire, enabling the development of highly specific diagnostic tests for early cancer detection, autoimmune diseases, and other conditions. With a foundation built on over two decades of research, Oncimmune has established itself as a leader in autoantibody biomarker discovery, offering a best-in-class engine for pharmaceutical partners seeking novel biomarkers for patient stratification and drug development. The company is publicly traded on the London Stock Exchange under the ticker ONC.L, reflecting its position as a pure-play diagnostics innovator. Looking ahead, Oncimmune's growth trajectory hinges on commercializing its platform through strategic collaborations and advancing its own diagnostic pipeline. The company's ability to translate its discovery capabilities into revenue-generating partnerships and FDA-cleared tests will be critical for value creation. While near-term financial performance remains dependent on partnership milestones, the long-term potential of its platform in precision medicine is significant. Key risks include the competitive landscape and the capital-intensive nature of diagnostic validation studies. Nonetheless, Oncimmune's unique technology and established track record position it well to capture value in the expanding liquid biopsy and biomarker markets.

Upcoming Catalysts (preview)

• Q3 2026New pharmaceutical partnership for biomarker discovery60% success
• Q2 2026Publication of clinical validation data for a lung cancer diagnostic test70% success
• Q4 2026Regulatory approval (CE marking) for an autoimmune disease diagnostic panel50% success